Derek R Johnson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4415144/publications.pdf

Version: 2024-02-01

361413 243625 2,104 67 20 44 citations h-index g-index papers 69 69 69 3824 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Glioblastoma survival in the United States before and during the temozolomide era. Journal of Neuro-Oncology, 2012, 107, 359-364.	2.9	632
2	2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know. Radiographics, 2017, 37, 2164-2180.	3.3	105
3	Pilocytic astrocytoma survival in adults: analysis of the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. Journal of Neuro-Oncology, 2012, 108, 187-193.	2.9	103
4	Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro-Oncology, 2012, 14, 808-816.	1.2	96
5	Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A populationâ€based analysis. Cancer, 2013, 119, 3489-3495.	4.1	95
6	Conditional probability of longâ€ŧerm survival in glioblastoma. Cancer, 2012, 118, 5608-5613.	4.1	79
7	Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. Cancer Genetics, 2011, 204, 13-18.	0.4	77
8	"Real world―use of a highly reliable imaging sign: "T2-FLAIR mismatch―for identification of IDH mutant astrocytomas. Neuro-Oncology, 2020, 22, 936-943.	1.2	77
9	Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro-Oncology, 2011, 13, 530-535.	1.2	74
10	Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI. American Journal of Neuroradiology, 2017, 38, 678-684.	2.4	63
11	Revisiting Adjuvant Radiotherapy After Gross Total Resection of World Health Organization Grade II Meningioma. World Neurosurgery, 2017, 103, 655-663.	1.3	55
12	Associations of High-Grade Glioma With Glioma Risk Alleles and Histories of Allergy and Smoking. American Journal of Epidemiology, 2011, 174, 574-581.	3.4	52
13	There is an exception to every rule—T2-FLAIR mismatch sign in gliomas. Neuroradiology, 2019, 61, 225-227.	2.2	52
14	Risk factors for meningioma in postmenopausal women: results from the lowa Women's Health Study. Neuro-Oncology, 2011, 13, 1011-1019.	1.2	50
15	Plenty of calcification: imaging characterization of polymorphous low-grade neuroepithelial tumor of the young. Neuroradiology, 2019, 61, 1327-1332.	2.2	48
16	Socioeconomic status and glioblastoma risk: a population-based analysis. Cancer Causes and Control, 2015, 26, 179-185.	1.8	46
17	Incorporation of Prognostic and Predictive Factors Into Glioma Clinical Trials. Current Oncology Reports, 2013, 15, 56-63.	4.0	32
18	Overall survival in patients with glioblastoma before and after bevacizumab approval. Current Medical Research and Opinion, 2018, 34, 813-820.	1.9	31

#	Article	IF	Citations
19	Frequency and Characteristics of Nodal and Deltoid FDG and ¹¹ C-Choline Uptake on PET Performed After COVID-19 Vaccination. American Journal of Roentgenology, 2021, 217, 1206-1216.	2.2	30
20	Relationship between cognitive function and prognosis in glioblastoma. CNS Oncology, 2013, 2, 195-201.	3.0	24
21	Medical Management of High-Grade Astrocytoma: Current and Emerging Therapies. Seminars in Oncology, 2014, 41, 511-522.	2.2	21
22	Recent Medical Management of Glioblastoma. Advances in Experimental Medicine and Biology, 2012, 746, 26-40.	1.6	20
23	Intracranial long-term complications of radiation therapy: an image-based review. Neuroradiology, 2021, 63, 471-482.	2.2	18
24	Mortality and Discharge to Home After Closed Brain Biopsy: Analysis of 3523 Cases from the State of California, 2003-2009. World Neurosurgery, 2013, 79, 110-115.	1.3	16
25	Case-Based Review: newly diagnosed glioblastoma. Neuro-Oncology Practice, 2015, 2, 106-121.	1.6	13
26	Polymorphous Low-Grade Neuroepithelial Tumor of the Young (PLNTY): Molecular Profiling Confirms Frequent MAPK Pathway Activation. Journal of Neuropathology and Experimental Neurology, 2021, 80, 821-829.	1.7	13
27	Pitfalls of a Mixed Metabolic Response at PET/CT. Radiographics, 2019, 39, 1461-1475.	3.3	12
28	Diffuse Gliomas of the Brainstem and Cerebellum in Adults Show Molecular Heterogeneity. American Journal of Surgical Pathology, 2021, 45, 1082-1090.	3.7	12
29	Preliminary exploration of a computerized cognitive battery and comparison with traditional testing in patients with high-grade glioma. Neuro-Oncology Practice, 2019, 6, 71-77.	1.6	10
30	Glioma response assessment: Classic pitfalls, novel confounders, and emerging imaging tools. British Journal of Radiology, 2019, 92, 20180730.	2.2	10
31	Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. Journal of Neuro-Oncology, 2018, 136, 373-378.	2.9	9
32	Diffuse Calvarial Hyperostosis in Patients with Spontaneous Intracranial Hypotension. World Neurosurgery, 2021, 146, e848-e853.	1.3	9
33	PET Imaging of Tumor Perfusion: A Potential Cancer Biomarker?. Seminars in Nuclear Medicine, 2020, 50, 549-561.	4.6	9
34	Case-based review: ependymomas in adults. Neuro-Oncology Practice, 2018, 5, 142-153.	1.6	8
35	Comparison of Radiologists and Other Specialists in the Performance of Lumbar Puncture Procedures Over Time. American Journal of Neuroradiology, 2021, 42, 1174-1181.	2.4	8
36	Rapid Symptomatic and Radiographic Evolution After Presumed Spontaneous Infarction of a Meningioma. Neurologist, 2012, 18, 409-412.	0.7	7

#	Article	IF	Citations
37	Uptake of AV-1451 in meningiomas. Annals of Nuclear Medicine, 2017, 31, 736-743.	2.2	7
38	Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma. Neuro-Oncology Practice, 2019, 6, 17-21.	1.6	7
39	Temporal Trends in Glioblastoma Survival. Neurologist, 2022, 27, 119-124.	0.7	7
40	Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors. Neuro-Oncology Advances, 2022, 4, .	0.7	7
41	Case-Based Review: meningioma. Neuro-Oncology Practice, 2016, 3, 120-134.	1.6	6
42	CSF dynamics disorders: Association of brain MRI and nuclear medicine cisternogram findings. NeuroImage: Clinical, 2020, 28, 102481.	2.7	5
43	Efficacy of 177Lu-Dotatate Therapy in the Treatment of Recurrent Meningioma. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 236-240.	2.4	5
44	Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of imaging in the management of progressive glioblastoma in adults. Journal of Neuro-Oncology, 2022, 158, 139-165.	2.9	5
45	<i>Neuro-Oncology Practice</i> Clinical Debate: long-term antiepileptic drug prophylaxis in patients with glioma. Neuro-Oncology Practice, 2020, 7, 583-588.	1.6	5
46	Diffuse Calvarial Hyperostosis and Spontaneous Intracranial Hypotension: A Case-Control Study. American Journal of Neuroradiology, 2022, 43, 978-983.	2.4	5
47	Neuro-Oncology Practice Clinical Debate: stereotactic radiosurgery or fractionated stereotactic radiotherapy following surgical resection for brain metastasis. Neuro-Oncology Practice, 2020, 7, 263-267.	1.6	4
48	Enlarging Perivascular Spaces Following Radiation Therapy in the Brain: A Report of 2 Cases and Literature Review. World Neurosurgery, 2020, 138, 436-439.	1.3	4
49	Case-based review: primary central nervous system lymphoma. Neuro-Oncology Practice, 2017, 4, 46-59.	1.6	3
50	Neuro-Oncology Practice Clinical Debate: FDG PET to differentiate glioblastoma recurrence from treatment-related changes. Neuro-Oncology Practice, 2021, 8, 518-525.	1.6	3
51	Cavernous Sinus Vascular Venous Malformation. American Journal of Neuroradiology, 2022, 43, 19-23.	2.4	3
52	Review of WHO 2016 Changes to Classification of Gliomas; Incorporation of Molecular Markers. , 2020, , 127-138.		2
53	18F-fluorodeoxyglucose PET/Computed Tomography. PET Clinics, 2022, 17, 249-263.	3.0	2
54	Dual-Energy CT Differentiates Contrast Staining From Hemorrhagic Conversion of Ischemic Stroke. Neurohospitalist, The, 2018, 8, 42-43.	0.8	1

#	Article	IF	CITATIONS
55	Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity. Cancer Chemotherapy and Pharmacology, 2020, 86, 375-382.	2.3	1
56	A focus on psychological needs of brain tumor patients and leveraging epidemiology. Neuro-Oncology Practice, 2020, 7, 463-464.	1.6	1
57	Growth hormone deficiency in a child with <scp>branchioâ€otoâ€renal</scp> spectrum disorder: Clinical evidence of <scp><i>EYA1</i></scp> in pituitary development and a recommendation for pituitary function surveillance. American Journal of Medical Genetics, Part A, 2021, 185, 261-266.	1.2	1
58	An 82â€yearâ€old man with a right frontal lobe rimâ€enhancing lesion. Brain Pathology, 2022, 32, e13021.	4.1	1
59	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Progressive Glioblastoma in Adults: Update of the 2014 Guidelines. Neurosurgery, 2022, 90, e112-e115.	1.1	1
60	Manifestations of radiation toxicity in the head, neck, and spine: An image-based review. Neuroradiology Journal, 2022, 35, 427-436.	1.2	1
61	Biologic therapy for malignant glioma. , 2012, , 102-113.		O
62	ED-25 * SOCIOECONOMIC STATUS MODIFIES THE IMPACT OF RACE/ETHNICITY ON GLIOBLASTOMA PROGNOSIS. Neuro-Oncology, 2014, 16, v71-v71.	1.2	0
63	PET Imaging of Hepatocellular Carcinoma. Current Radiology Reports, 2019, 7, 1.	1.4	0
64	Neuro-Oncology Practice Clinical Debate: Early treatment or observation for patients with newly diagnosed oligodendroglioma and small-volume residual disease. Neuro-Oncology Practice, 2021, 8, 11-17.	1.6	0
65	Cerebral malaria with extensive subcortical microhemorrhages. Oxford Medical Case Reports, 2021, 2021, omab028.	0.4	0
66	Intracranial neuroendocrine tumour simulating meningioma for several years: an overview of diagnosis and treatment. BJR \mid case Reports, 2022, 8, .	0.2	0
67	A 76â€yearâ€old male with multiple enhancing brain lesions. Brain Pathology, 2022, 32, e13063.	4.1	0